Oncostatin M (OSM) is an interleukin-6 (IL-6) type cytokine originally described by its capacity to inhibit melanoma proliferation in vitro. Here, the mechanisms involved in resistance to growth inhibition by OSM were analysed for the first time on a large panel of metastatic melanoma cell lines. OSM resistance did not strictly correlate with IL-6, interferon-c or tumor necrosis factora resistance. Rather, it correlated with a specific loss of the OSM receptor-b (OSMRb) subunit, in conjunction with a lower level of histone acetylation in the OSMRb promoter region. Treatment of various OSM-resistant melanoma cells with the histone deacetylase inhibitor Trichostatin A increased activity and histone acetylation of the OSMRb promoter as well as expression of OSMRb mRNA and protein, allowing OSM to activate the signal transducer and activator of transcription 3 (STAT3) and to inhibit proliferation. Other defects associated with OSM resistance were identified at the level of OSMRb transcription or protein expression, as well as downstream of or parallel to STAT3 activation. Altogether, our results suggest a role for OSM in the prevention of melanoma progression and that metastatic melanoma cells could escape this growth control by the epigenetic silencing of OSMRb.
Introduction
Melanoma is an aggressive malignancy with poor prognosis owing to resistance to chemotherapy. Although the treatment of primary melanoma essentially relies on surgery, at the stage of lymph node invasion (stage III), an adjuvant treatment with interferon a (IFNa) is usually given but has only a modest success rate (Chudnovsky et al., 2005) . Therefore, clinical trials have evaluated immunotherapeutic approaches based on (i) vaccination, where melanoma or dendritic cells are modified to express HLA or tumor antigens, costimulatory molecules or cytokines, and (ii) adoptive therapy using tumor-infiltrating lymphocytes (TILs) (Nawrocki et al., 2000; Yannelli and Wroblewski, 2004) . These clinical trials gave encouraging results, but many patients did not respond because of potent tumor escape from immune recognition (Yannelli and Wroblewski, 2004) .
A large number of cytokines have proven to be effective in restricting melanoma progression in vivo, such as interleukin (IL)-2, IL-12, IFNa and IFNg, TNFa family members and IL-6 family members (Mule et al., 1990; Nawrocki et al., 2000; Ozbek et al., 2001; Yannelli and Wroblewski, 2004) . Tumor rejection and prevention of metastasis were also demonstrated in mice sarcoma models with systemic IL-6 administration (Mule et al., 1990) . Similarly, transfer of the IL-6 and IL-6 receptor-a gene into melanoma cells led to a lower rate of tumor growth in mice and enhanced survival (Nawrocki et al., 2000; Ozbek et al., 2001) . In vitro, melanocytes and early-stage (radial growth phase) melanoma cell lines are inhibited in their growth by IFNa and IFNg, TNFa and IL-6-type cytokines, whereas cell lines from advanced-stage lesions are often resistant to these cytokines, suggesting an acquired 'multicytokine resistance' during melanoma progression (Lu et al., 1993; Bani et al., 1996) .
Oncostatin M (OSM) is an IL-6-type cytokine, produced mainly by activated monocytes and lymphocytes, and first identified by its capacity to inhibit melanoma cell growth in vitro (Zarling et al., 1986) . OSM is now considered as a multifunctional cytokine implicated in the activation, proliferation and/or differentiation of several cell types, such as hepatocytes, osteoblasts or lung epithelial cells (Grant and Begley, 1999; Tanaka and Miyajima, 2003) . OSM is more active than IL-6 in inhibiting the proliferation of numerous solid tumor cell lines derived from breast or lung cancer, hepatoma, osteosarcoma or melanoma (Grant and Begley, 1999) . However, relatively few studies have focused on the antitumor effects of OSM, and the mechanisms regulating such activities are only poorly understood.
All IL-6-type cytokines share the signal transducing receptor subunit gp130 and receptor specificity is provided by additional receptor chains: IL-6Ra for IL-6 and OSM receptor (OSMR)b for OSM (Heinrich et al., 2003; Tanaka and Miyajima, 2003) . OSM is most closely related to another IL-6-type cytokine, leukemia inhibitory factor (LIF), and both cytokines can transduce a signal via the LIF receptor composed of gp130 and LIFRa. Once recruited, these receptor complexes allow activation of Janus protein tyrosine kinases (Jak), and subsequently signal transducer and activator of transcription (STAT) (mainly STAT3) and MAPK (mainly extracellular signal-regulated kinase (ERK) 1/2) (Klausen et al., 2000; Heinrich et al., 2003; Tanaka and Miyajima, 2003) . In melanoma or other solid tumors, the key role of STAT3 in mediating the growth inhibitory effect of IL-6 or OSM has been demonstrated (Kortylewski et al., 1999) , whereas activation of ERK 1/2 could counterbalance that of STAT3 by inducing mitogenic signals (Kim and Baumann, 1999) .
In metastatic melanoma, IL-6 resistance seems to be largely a consequence of an altered STAT signaling or STAT-induced gene transcription. Thus, in various IL-6-resistant melanoma cell lines, IL-6 is still able to activate its receptor as well as STAT3, but it fails to induce the cyclin-dependent kinase inhibitor p21
WAF1
, a STAT3 gene target implicated in growth inhibition by IL-6 (Florenes et al., 1999) . One study showed that melanoma cells derived from advanced-stage lesions are often resistant to growth inhibition by OSM and that OSM resistance does not always correlate with IL-6 resistance (Lu et al., 1993) , suggesting a defect in an OSM-specific pathway. We previously showed that responsiveness to IL-6-type cytokines can be increased by histone deacetylase (HDAC) or DNA methyltransferase inhibitors (Blanchard et al., 2002; Blanchard et al., 2003) . Indeed, these inhibitors can induce expression of several epigenetically silenced tumor suppressor genes, resulting in cell cycle arrest and differentiation (Jaenisch and Bird, 2003; Blanchard and Chipoy, 2005) . Our data indicated that the promoters for gp130 or LIFRa can be epigenetically silenced in normal or transformed cells, concomitant with a defect in receptor expression and STAT signaling (Blanchard et al., 2002; Blanchard et al., 2003) .
Here, we analysed 22 metastatic melanoma cell lines for growth inhibition by IFNg, TNFa and IL-6 family members. Resistance to OSM was not always associated with resistance to IL-6, IFNg or TNFa. Rather, it correlated with a loss of OSMRb expression, associated with histone deacetylation in the OSMRb gene promoter region.
Results
OSM resistance does not strictly correlate with resistance to other cytokines In a first attempt to describe the responsiveness of melanomas to growth-inhibitory cytokines, we analysed the proliferation of metastatic melanoma cell lines obtained from the lymph nodes of 22 patients (stage III) who were enrolled in a previously described phase II/III randomized clinical trial Labarriere et al., 2002) . The WM-266-4 metastatic cell line was used as a positive control. Preliminary experiments indicated that a maximum growth inhibition was obtained with 50 ng/ml OSM for 3 days on WM-266-4 and M140 cells (IC 50 values of 1 ng/ml; data not shown). Therefore, these conditions were selected for further analyses. As shown in Figure 1a and Table 1 , OSM appeared to be a potent growth inhibitor, with 15 cell lines (65%) being inhibited by more than 15% (range 18-92%) and eight cell lines (35%) being resistant to OSM (less than 15% inhibition, not statistically significant). In contrast, our analysis on primary melanoma cells (seven cell lines) indicated that they were all sensitive to growth inhibition by OSM (Heymann et al., 1995) .
OSM was about twofold more active than IL-6 in reducing thymidine incorporation by metastatic melanoma cells (Table 1) , and growth inhibition by OSM was significantly correlated with growth inhibition by IL-6 (Po0.001). However, 2/8 cell lines (M134 and M170) were resistant to OSM but not to IL-6 ( Figure 1a) and conversely, some cell lines were resistant to IL-6 (less than 15% inhibition) but not to OSM (see the M197 or M203 cell lines in Table 1 ). LIF never showed any effect on the growth of these cells (data not shown). Growth inhibition by IFNg or TNFa did not correlate with that observed after OSM treatment ( Figure 1a and Table 1 ). In fact, all OSM-resistant cell lines were growth-inhibited by either IFNg or TNFa or both. Therefore, the mechanisms involved in OSM resistance appeared specific, suggesting defects in its receptor or signaling pathways.
OSM resistance is associated with the loss of OSMRb and STAT3 signaling Melanoma cell lines were then analysed for the early phosphorylation/activation of STAT3 and ERK 1/2 induced by short-term treatment with IL-6-type cytokines ( Figure 1b-d and Table 1 ). STAT3 and ERK 1/2 were expressed in all cell lines tested ( Figure 1b and data not shown). Activation of STAT3 and ERK 1/2 by OSM was always stronger than by IL-6 or LIF (see the M140 cell line in Figure 1b as a representative example). Growth inhibition by OSM or IL-6 was always associated with a corresponding activation of STAT3 (Table 1) . In sharp contrast, OSM resistance was almost always associated with a loss of STAT3 activation by OSM (in seven out of eight cell lines; see the M128 and M170 cell lines in Figure 1b as representative examples), whereas IL-6 resistance was associated with a loss of STAT3 activation by IL-6 in half of the cell lines (six on 12). Therefore, these results suggested that in seven out of eight cases, OSM resistance was associated with a defect occurring upstream of STAT3. For the M183 cell line, resistance to OSM was presumably associated with defects occurring downstream of or parallel to STAT3.
A high basal level of ERK 1/2 activation could be detected in 54% of the cell lines (see the M170, M128 and M200 cell lines in Figure 1b and d as representative examples). In agreement with previous reports (Chudnovsky et al., 2005) , this modification correlated well with an activating mutation in B-Raf (Table 1 and data not shown, P ¼ 0.02), an upstream activator of the mitogen-induced extracellular kinase/ERK pathway. This constitutively high level of phosphorylated ERK 1/2 did not allow for further activation by IL-6-type cytokines and was observed in either OSM-resistant (M170 and M128 cells in Figure 1b) or sensitive cell lines (see the M200 cell line which is B-Raf-mutated but OSM-sensitive; Figure 1d and Table 1 ).
Because defects in OSM-resistant cell lines could be present at the receptor level, we next analysed the relative mRNA expression levels for various IL-6-type receptor subunits by quantitative reverse transcription-polymerase chain reaction (RT-PCR). Individual expression levels are shown in Supplementary Figure 1a ). The correlation between OSMRb mRNA expression and growth inhibition by OSM was categorical (cutoff 15% of growth inhibition) and not linear (Supplementary Table 1a ). This defect appeared specific, as gp130 transcripts were expressed at similar levels, regardless of whether the cell lines were resistant or sensitive to OSM or IL-6. Only one OSM-resistant cell line (M120) expressed OSMRb mRNA at a level close to the M140 reference cell line (relative expression 0.9). OSM-resistant cell lines also expressed a lower amount of LIFRa mRNA (9.4-fold reduction), but this was not significant (P ¼ 0.07). In fact, five out of 14 OSMsensitive cell lines did not express detectable LIFRa mRNA (Supplementary Figure 1a) , indicating that the LIFRa subunit was not necessarily used by OSM to mediate growth inhibitory signals. In IL-6-resistant cell lines, the mean IL-6Ra mRNA expression was slightly decreased (1.9-folds) albeit not significantly (P ¼ 0.17).
In order to assess whether OSMRb mRNA expression by cultured cell lines reflected the in vivo situation, immunohistochemical analyses of OSMRb were performed in biopsies from primary melanomas and corresponding invaded lymph nodes from which the cell lines were established. We observed that the expression of OSMRb by tumor cells in lymph nodes was lost in five out of 14 cases (Supplementary Table 2 and see also Table 2 ). In contrast, the four primary melanoma biopsies tested expressed OSMRb similarly (Supplementary Table 2 ), suggesting that OSMRb mRNA expression in melanoma cell lines correlated well with OSMRb protein expression in lymph node biopsies, but not in primary tumors.
The OSMRb promoter is silenced by histone deacetylation in OSM resistant cells Thus far our results suggested that a defect in OSMRb expression was the major molecular event leading to 
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A Lacreusette et al OSM resistance in stage III melanoma cell lines. Because we previously showed that gp130 and LIFRa expression can be regulated by epigenetic mechanisms in various cells (Blanchard et al., 2002; Blanchard et al., 2003) , we asked whether the OSMRb gene could be similarly controlled in melanoma.
To address this issue, we first cloned and characterized the human OSMRb promoter (Figure 3 ). This promoter was found to be immediately 5 0 of the human OSMRb cDNA (Mosley et al., 1996) , and to contain a CpG island and a potential transcription start site (Figure 3a and b) . Indeed, the À693 to þ 229 segment (hOSMRb Pro2), designed to contain the majority of the CpG island (Figure 3a ), was active in transfection experiments when inserted upstream of the luciferase gene (Figure 3a and c). In comparison to OSM-sensitive cell lines with a high level of OSMRb mRNA (M140, M200 and M117), activity of this promoter was lower in three out of four OSMRb low cell lines that could be efficiently transfected (M128, M102 and M170, Figure 3c ). Moreover, trichostatin A (TSA), a broad HDAC inhibitor, induced promoter activity in these OSM-resistant cells, although this activity remained low in M170 cells. In M210 OSM-resistant cells, activity of the OSMRb promoter was as high as in OSM-sensitive cells and TSA did not induce this activity (Figure 3c ).
We also tested a longer promoter construct (À1229 to þ 229; hOSMRb Pro1) containing 536 additional bases preceding the CpG island ( Figure 3a ). This segment was inactive in all cell lines tested ( Figure 3a and data not shown), suggesting the presence of inhibitory elements upstream of the CpG island, the precise location and function of which are currently unknown.
In the six OSM-resistant cell lines that expressed a low level of OSMRb mRNA, chromatin immunoprecipitations (ChIPs) demonstrated a low level of acetylated histone H3 and H4 associated with the promoter region of OSMRb (Figure 4a, top panel) . In comparison to three OSM-sensitive cell lines with high levels of OSMRb mRNA, the levels of acetylated histone H3 and H4 were reduced 2.4-and 3.5-fold, respectively. Importantly, TSA induced OSMRb-associated acetylation of histones in five out of six OSMRb low cell lines to a level comparable to or even higher than in the OSMRb high cells (Figure 4a ). In correlation with the increased histone acetylation and promoter activity, TSA also induced OSMRb mRNA expression in four out of six OSMRb low cell lines, although this level remained low in the case of the M196 cell line (Figure 4a , bottom panel). In the OSMRb high cell lines, TSA did not significantly modify the level of histone acetylation, in correlation with a stable expression of Cells were treated for 15 min with cytokines. STAT3 Tyr705 phosphorylation was determined by Western blotting and quantified by densitometry using the OSM-treated WM266.4 cell line as the 100% internal reference: -(p5%), + (5-50%) and ++ (X50%).
c V600E mutation within B-Raf was detected by RT-PCR.
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OSMRb mRNA (Figure 4a ). In the M128 cell line treated with TSA, the appearance of the OSMRb protein at the cell surface was observed at a level comparable to that observed in the WM266.4 cell line used as a positive control (Figure 4b ). TSA also increased gp130 cell surface expression in M128 cells two-fold (Figure 4b ). Altogether, these results indicated that HDACs were implicated in the repression of the OSMRb gene in various OSM-resistant cells. The functionality of OSMRs induced by TSA treatment was next evaluated by STAT3 activation and by growth inhibition. In four OSM-resistant cell lines (M102, M128, M196 and M134), TSA treatment restored a prominent phosphorylation of STAT3 (Figure 5a ). In three of them, TSA also restored growth inhibition by OSM, although this was observed at a high TSA concentration in the case of M196 cells (Figure 5b ). This growth inhibition by OSM was observed despite or in addition to the growth inhibition observed after TSA treatment (data not shown). In TSA-treated M196 cells, we also observed activation of STAT3 by LIF (Figure 5a ), in correlation with an increased expression of LIFRa mRNA (data not shown). In contrast to its effect on OSM or LIF responses, TSA reduced STAT3 activation by IL-6 in the M128 and M170 cell lines (Figure 5a ). This differential effect of TSA on cytokine responses was further supported by the observation that among the 13 melanoma cell lines treated with TSA, seven showed an increased OSMRb mRNA expression, six an increased LIFRa, three an increased gp130 and four a decreased IL-6Ra mRNA expression (data not shown). By Western blot, no modification in STAT3 protein expression were ever observed after TSA treatment (data not shown), suggesting that modification of cytokine responsiveness by TSA was largely due to increased or decreased receptor expression.
OSM responsiveness can be regulated by additional mechanisms
The results obtained with some OSM-resistant cell lines revealed additional regulatory mechanisms that did not necessarily depend on histone deacetylation of the OSMRb gene.
Indeed, the M210 OSMRb low cell line was not sensitive to TSA treatment in terms of increased OSMRb promoter activity (Figure 3c ), histone acetylation, OSMRb expression (Figure 4a ) or STAT3 activation (data not shown). The whole OSMRb gene was not deleted in these cells, because PCR amplification of the OSMRb promoter region gave positive results (Figure 4a) . Therefore, silencing of the OSMRb gene was more likely the result of other genetic and/or epigenetic mechanisms resistant to TSA treatment.
A second case is the M170 cell line that responded well to the TSA treatment by an increase of histone acetylation (Figure 4a) . However, OSMRb promoter activity remained low (Figure 3c) , expression of OSMRb mRNA remained unchanged (Figure 4a) , and there was neither activation of STAT3 (Figure 5a ) nor growth suppression by OSM (data not shown). Therefore, in addition to a TSA-sensitive OSMRb gene silencing, a specific defect in OSMRb gene transcription was detected in these cells.
The behavior of the M134 cell line was surprising because TSA treatment increased histone acetylation, Table 2 ) and were therefore resistant in terms of STAT3 activation or growth inhibition by OSM (Figure 5c and Table 1) . After TSA treatment, we observed an induced activation of STAT3 by OSM and LIF (Figure 5Ca ), but without growth inhibition (data not shown), and neutralizing antibodies against the LIFRa totally prevented STAT3 activation by OSM or LIF (Figure 5Ca ).
These results strongly suggested that TSA allowed the recruitment of the gp130-LIFRa complex by OSM, despite the fact that we could not detect the LIFRa by RT-PCR in these cells, even after TSA treatment. In an attempt to force the cell surface expression of OSMRb, we stably transfected the OSMRb cDNA in these cells. OSMRb mRNA and cell surface protein were increased in OSMRb-transfected M120 cells (data not shown), allowing STAT3 activation by OSM but not by LIF (Figure 5Cb ). However, OSM was again unable to inhibit the growth of the OSMRb overexpressing cells (Figure 5Cc ). Together, these results suggested the presence of two defects in M120 cells: one at the posttranscriptional level for OSMRb expression and another downstream of or parallel to STAT3 activation.
Discussion
In this study, we provide evidence that OSM is an important regulator of melanoma growth. This cytokine is very active in inhibiting melanoma cell proliferation, by a mechanism which presumably depends on the successful recruitment and activation of the OSMRb/ gp130 complex and subsequently of STAT3. OSM appears more active than IL-6 in reducing melanoma growth in vitro, whereas LIF is totally inactive.
The key role of OSM in melanoma growth was confirmed by the high percentage (35%) of metastatic cell lines that were resistant to OSM-mediated growth inhibition with a concomitant decrease in OSMRb mRNA expression (29%) and STAT3 activation (30%). Similarly, melanoma-invaded lymph node biopsies corresponding to the OSMRb low cell lines revealed a lower expression of OSMRb. In contrast, all the primary melanoma cell lines tested so far were sensitive to OSM and high expression of OSMRb was found in primary melanoma biopsies, suggesting that melanoma progression toward a metastatic state is accompanied by silencing of the OSMRb gene. These results indicate that specific mechanisms target the OSMRb receptor and not the pathways used by other growth inhibitory cytokines such as IL-6, IFNg or TNFa. They also help to explain why the phenotype of 'multicytokine resistance' was not observed in our studies. 
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In previous studies conducted in numerous normal or transformed cells, such as hepatoma cells, gp130 or OSMRb downregulations were rarely observed, in contrast to the LIFRa gene that was frequently epigenetically silenced (Blanchard et al., 2002 (Blanchard et al., , 2003 . In stage III melanoma, both LIFRa and OSMRb were found frequently downregulated, but only the OSMRb recruitment correlated with OSM-mediated growth inhibition. TSA treatment re-induced OSMRb promoter acetylation (in 5/8 resistant cell lines) and mRNA levels (in 4/8 resistant cell lines), resulting in the recovery of OSM sensitivity. Thus, we identified epigenetic modifications in the OSMRb promoter, i.e. histone deacetylation, as a major regulatory mechanism responsible for OSMRb silencing and OSM resistance. The OSMRb promoter structure thus appears similar to the one already described for the gp130 and LIFRa genes (Blanchard et al., 2002) . The LIFRa and OSMRb genes are located within 500 kbp on chromosome 5 (in 5p13), suggesting a common ancestral gene, whereas the gp130 gene is located near them in 5q11. Their TATA-less promoter regions are all composed of a CpG island associated with differential histone acetylation sensitive to HDAC inhibition (Blanchard et al., 2002 (Blanchard et al., , 2003 . However, the OSMRb promoter is the only one to be negatively regulated by a region immediately upstream of the CpG island. It remains to be determined which molecular events induce the epigenetic loss of LIFRa and/or OSMRb in some tumors like melanoma or hepatoma. This loss could be related to enhanced expression of tissue-specific HDACs and/or associated regulatory factors (Blanchard and Chipoy, 2005) .
Analysis of IFN or IL-6 resistance in melanoma revealed major defects at the level of STAT activation or downstream at the level of induction of gene transcription (Wong et al., 1997; Florenes et al., 1999; Pansky et al., 2000; Bohm et al., 2001) . Our results confirm that IL-6 resistance is often independent of IL-6Ra loss, and 50% of these resistant cell lines can still activate STAT3 in response to IL-6. Interestingly, IL-6Ra expression and STAT3 activation by IL-6 were usually decreased by TSA (Figure 5a ). In fact, among the genes that can be regulated by HDAC inhibitors (2-9% of the genome), equal fractions are activated or repressed (Chambers et al., 2003; Blanchard and Chipoy, 2005) . Inhibition of gene expression by TSA is prominent for proinflammatory mediators such as TNFa, IL-6, IL-12 or nitric oxide, and implies inhibition of the transcription factor nuclear factor-kappa B (NF-kB) (Blanchard and Chipoy, 2005) . It is therefore tempting to speculate that both IL-6 and IL-6Ra are mainly controlled by NF-kB and thus inhibited by TSA, whereas LIFRa, OSMRb and possibly gp130 are mostly sensitive to inhibition by HDACs and are thus activated by TSA.
In addition to the major HDAC-dependent loss of OSMRb, additional mechanisms are also implicated in OSM resistance. Indeed, we detected abnormalities in several stages of OSMRb production and activation, such as TSA-resistant gene silencing (M210 cell line), transcriptional inactivation (M170 cell line), inefficient protein expression (M120 cell line) and defects downstream of or parallel to STAT3 (M183 cell line). The inefficient OSMRb protein expression in M120 cells could rely on Jaks deficiency or low availability as described previously (Radtke et al., 2002) . Other defects such as point mutations in the OSMRb gene could also alter its expression in certain melanomas. To our knowledge, there is no report describing mutation in this gene and only one study described mutations in the LIFRa gene that alter mRNA stability, resulting in the absence of the LIFRa protein and in the impairment of STAT3 activation by LIF (Dagoneau et al., 2004) . Additional experiments are needed to discriminate between these possibilities.
Defects downstream of STAT3 are presumably at the level of key cell cycle regulatory proteins. We observed that OSM treatment of sensitive melanomas effectively blocks the cells in the G1 phase of the cell cycle, but there was no induction of either p21 WAF1 or p27 KIP1 (data not shown) as described elsewhere (Florenes et al., 1999; Kortylewski et al., 1999; Klausen et al., 2000; Chipoy et al., 2004) . Therefore, a more global analysis of gene expression is necessary to identify the genes implicated in OSM-mediated growth inhibition and potentially deregulated in certain resistant melanoma cells. Additionally, STAT3 has been described to be acetylated and its transcriptional activity is inhibited by HDACs (Yuan et al., 2005) . Therefore, it is possible that HDACs inhibit OSM signaling not only by reducing OSMRb transcription but also by preventing expression of STAT3 target genes. Defects parallel to STAT3 could rely on other OSM-activated signal transduction pathways such as STAT1, STAT5, ERK 1/2, AKT, p38MAPK, JNK or PKCd (Grant and Begley, 1999; Heinrich et al., 2003; Tanaka and Miyajima, 2003; Chipoy et al., 2004; Boing et al., 2006) . Despite the large incidence and the key role of activating mutations in B-Raf upstream of ERK 1/2 in the etiology of melanoma (Chudnovsky et al., 2005) , these modifications do not prevent growth inhibition by OSM.
Accumulating evidences have shown that constitutively active STAT3 contributes to the development of various cancers, including melanoma, by inducing tumor cell survival, proliferation, angiogenesis, metastasis and immune evasion (Bromberg and Darnell, 2000; Niu et al., 2002; Kortylewski et al., 2005) . Because STAT3 was not found constitutively active in our panel of melanoma cell lines, it can be anticipated that the mode of STAT3 activation, for example, transient activation following OSM treatment or prolonged stimulation resulting in constitutively active STAT3, will dictate the outcome on tumor progression. Alternatively, the contradictory effects of STAT3 on tumor growth could depend on other co-stimulated cellular factors that determine the target genes of STAT3. Understanding of this important phenomenon is certainly crucial in the course of cancer treatment and prognosis.
In conclusion, our results suggest that OSM is an important factor in the control of melanoma growth. Silencing and loss of OSMRb are major events associated with OSM resistance in metastatic melanoma and they could lead to a growth advantage during particular inflammatory stages or anticancer immune reactions. HDAC inhibitors have been used in phase I-II clinical trials for the treatment of various hematological or solid malignancies such as melanoma (Sandor et al., 2002; Marks et al., 2004) . They have shown antitumor activities against melanoma in vitro and in vivo and represent a promising therapeutic approach for patients with malignant melanoma (Yoshida et al., 2001; Boyle et al., 2005) . Their capacity to restore OSMRb expression and growth inhibition by OSM could help to restrain the progression of this aggressive malignancy.
Materials and methods

Cell lines and reagents
Metastatic melanoma cell lines were established from tumorinvaded lymph node fragments as described previously (Gervois et al., 1990; Dreno et al., 2002; Labarriere et al., 2002) . Melanoma cell lines were established before injection of autologous TILs plus IL-2 or IL-2 only. The metastatic melanoma WM-266-4 cell line was purchased from the American Type Culture Collection (LGC Promochem, Molsheim, France). All cells were maintained in RPMI 1640 or Dulbecco's modified Eagle's medium (Sigma, Lyon, France) supplemented with 10% fetal calf serum and 2 mM Lglutamine. All recombinant human cytokines were from R&D Systems (Lille, France). TSA was from Calbiochem (La Jolla, CA, USA).
Cell proliferation assay
The antiproliferative activity of OSM (50 ng/ml), IL-6 (50 ng/ ml), LIF (100 ng/ml), IFNg (50 ng/ml) and TNFa (50 ng/ml) was measured by [ 3 H]-thymidine incorporation after 3 days of treatment as described previously (Heymann et al., 1995; Blanchard et al., 2002) . For sensitization of resistant cells to OSM, increasing doses of TSA were incubated with OSM (50 ng/ml) and [ 3 H]-thymidine incorporation was measured after 48 h of treatment.
Western blotting
After 4 h of serum deprivation and 15 min of cytokine stimulation, control or 24 h TSA-pretreated cell monolayers were lysed in RIPA buffer. For the blockade of LIFRa, cells were preincubated with neutralizing anti-LIFRa antibodies (Blanchard et al., 1997) for 90 min before cytokine stimulation. Equal amounts of protein lysates were separated on 10% sodium dodecyl sulfate-polyacrylamide gels and transferred to polyvinylidine difluoride membranes (Immobilon-P, Millipore, Bedford, MA, USA). Western blotting was performed using antibodies against phospho-STAT3 (Tyr705), phospho-ERK 1/2 (Thr202/Tyr204) (Cell Signaling, Beverly, MA, USA), STAT3 (BD Bioscience, Le Pont de Claix, France) or ERK 1/2 (Cell Signaling). Digital densitometry of the patterns was analysed with the NIH Image software. To enable the quantitative comparison of cytokine responsiveness among cell lines, an OSM-treated WM266.4 cell lysate was used as an internal reference (100% level).
Real-time quantitative RT-PCR Total RNA was extracted from control or 24 h TSA-treated cells by Trizol reagent (Invitrogen, Cergy Pontoise, France). Retrotranscription was performed using 2 mg of RNA, random hexamers and SuperScript II reverse transcriptase (Invitrogen). Relative quantification of OSMRb, gp130, LIFRa and IL-6Ra expression was carried out using Brilliant SYBR Green QPCR Master Mix (Stratagene Europe, Amsterdam, The Netherlands) with exon-exon junction-spanning primers (Supplementary Table 1 ) and an Mx4000 multiplex quantitative PCR instrument (Stratagene). Average threshold cycle (C T ) values from duplicate PCR reactions were normalized to average C T values for three housekeeping genes (b-actin, b-2-microglobulin and RPLPO) from the same cDNA preparations. The stability of these housekeeping genes was approved by the BestKeeper software (Pfaffl et al., 2004) . Thus, the relative expression ratio of a target gene was calculated based on the PCR efficiency (E) and the C T deviation between a given cell line (x) and a reference cell line (calibrator), expressed in comparison with the geometric mean of the housekeeping genes (Pfaffl, 2001) :
Several RNA extracts were independently analysed and reproducibility was confirmed with a correlation coefficient r ¼ 0.99.
The V600E mutation in B-Raf was detected as described previously (Jarry et al., 2004) .
Cloning of the human OSMRb cDNA and promoter
The hOSMRb cDNA, cloned into the pDC409 vector (a kind gift from Dr H Baumann, RPCI, Buffalo, USA), was subcloned into the EcoRV and NotI sites of the pcDNA3.1/ Hygro ( þ ) vector (Invitrogen).
The 5 0 flanking sequence of the hOSMRb cDNA (NM_003999) was obtained using the BLAT alignment tool from UCSC Genome Browser (http://genome.ucsc.edu/). Putative transcription start site was predicted using the Human Core-promoter Finder (http://rulai.cshl.org/), whereas transcription factor binding sites were predicted using the MatInspector of Genomatix (http://www.genomatix.de/). Two overlapping segments were amplified by PCR using genomic DNA from the M88 melanoma cell line. These segments contained the nucleotides from position À1229 to þ 229 (hOSMRb Pro1) and -693 to þ 229 (hOSMRb Pro2), relative to the transcription start site. They were then cloned into the pCR-Blunt II-TOPO vector (Invitrogen) and subcloned into the KpnI and XhoI sites of the luciferase reporter plasmid pGL3-Basic (Promega, Charbonnieres, France). All constructs were confirmed by sequence analysis.
Luciferase reporter assay Melanoma cell lines were transiently transfected using FuGENE6 (Roche Diagnostics, Meylan France) or LipofectAMINE (Invitrogen) with empty or hOSMRb promoterdriven pGL3-Basic which encodes Firefly luciferase as a reporter, together with a 50:1 ratio of Renilla luciferase vector (pRL-CMV; Promega) as an internal control. Luciferase activity was measured 48 h following transfection and 24 h after TSA treatment of OSMRb low cells, with the DualLuciferase kit (Promega) and a single-sample luminometer (Berthold Technologies, Bad Wildbad, Germany). Whenever possible, each transfection was reproduced three times and human OSMRb promoter activity was calculated as a ratio to Renilla luciferase activity.
Quantitative ChIP assay
ChIP analysis was performed according to a modified protocol of Upstate Biotechnology (Dundee, UK) and essentially as described previously (Blanchard et al., 2002) . Control or 24 h TSA-treated melanoma cell lines were fixed, lysed and sonicated to shear DNA. After 1 h of preclearing with 50 ml of protein G-sepharose (Invitrogen), samples were incubated overnight at 41C with 5 mg of anti-acetylated histone H3, antiacetylated histone H4 (Upstate Biotechnology) or irrelevant rabbit IgG (Sigma) and 2 mg of salmon sperm DNA (Sigma). Immune complexes were recovered with 100 ml of salmon sperm DNA-saturated protein G-sepharose. After elution and purification, the ChIP-captured DNA was then screened for hOSMRb promoter fragments by real-time PCR analysis using specific primers (sense 5 0 -TTGAAGATTGGATGGCATTT-3 0 and antisense 5 0 -AAAACGTGTTTGAACCGAA-3 0 ) located in the hOSMRb Pro2 segment described above. Serial dilutions of input DNA generated a standard curve used to determine the relative amount of precipitated DNA. Duplicates for both standards and the samples were simultaneously amplified and at least two independent immunoprecipitations were analysed.
Flow cytometric analysis
Expression of receptor subunits at the cell surface was monitored using an antihuman gp130 antibody (B-R3, mouse IgG2a, Diaclone Research, Besanc¸on, France) or an antihuman OSMRb antibody (P1, rabbit serum, Amgen Inc., Thousand Oaks, USA) with mouse IgG (BD Biosciences) or rabbit pre-immune serum as isotype controls, respectively. These primary antibodies were revealed by anti-mousephycoerythrin and anti-rabbit-Alexa488, respectively. Cellassociated fluorescence was acquired by a FACScalibur fluorocytometer (BD Biosciences) and analysed using CellQuest software.
Immunohistochemistry
Five micrometer sections of formalin-fixed, paraffin-embedded primary melanoma biopsies or frozen melanoma-invaded lymph nodes were incubated for 30 min with a goat antihuman OSMRb antibody (Santa Cruz Biotechnology, Heidelberg, Germany) diluted 1/25 in phosphate-buffered saline-bovine serum albumin 0.1% or with diluent alone as a negative control. The rinsed sections were then incubated for a further 30 min with a 1/200 dilution of biotinylated rabbit antigoat antibody (DakoCytomation, Trappes, France). Immunostaining for OSMRb was revealed using streptavidine-HRP and diaminobenzidine (DakoCytomation), and nuclei were counterstained with hematoxylin. All sections were examined by three investigators, one of whom (BD) was blinded to the molecular and clinical data.
Statistical analyses
Data are expressed as means7s.d. and frequencies. Continuous data were compared using the Wilcoxon test. Categorical data were compared using the Fisher exact test. Correlations between continuous data were accessed using the Spearman rank test. A value of Po0.05 was considered as significant.
